Acquisition of Geadic Biotech, holder of GynEC®-DX

Reig Jofre takes over from Oryzon and gets control of 100% of GynEC®-DX, a molecular diagnostic test for early detection of endometrial cancer.

  • The transaction was conveyed by Reig Jofre taking control of 100% of Geadic Biotech, holder of GynEC®-DX, and whose shareholders to date were 50% Reig Jofre and 50% Oryzon Diagnostics SL (ODSL).
  • Through this transaction, Oryzon completes its divestment in the area of Molecular Diagnostics.
  • GynEC®-DX is a development initiated in 2006 by Oryzon Genomics and Reig Jofre in collaboration with the research teams of several university hospitals, such as Barcelona-based University Hospital Valle de Hebron and University Hospital Bellvitge.
  • The transaction amounted to 2.2 million euros, which Reig Jofre financed by own resources and the commitment to deliver before 31 January 2017, 221,518 shares of Reig Jofre to some of the old shareholders of the project.

Download the full document (PDF)